Skip to main content
Premium Trial:

Request an Annual Quote

Nuvelo Nets $26M From Stock Offering

NEW YORK, Oct. 7 (GenomeWeb News) - Nuvelo, the company created when Hyseq merged with Variagenics in November 2002, announced today that it has raised $26 million as the net proceeds after sales of 11.5 million new shares of its stock.


The company, based in Sunnyvale, Calif. said it plans to use the proceeds of the previously-announced financing for clinical trials of its lead drug candidate. 


In August, Nuvelo said it would sell its pharmacogenomics assets from Variagenics and its microarray assets from Hyseq in order to focus on drug development. (See the article in SNPtech Reporter 08-07-03).


The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.